Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Masaya Koshizaka; Ko Ishikawa; Ryoichi Ishibashi; Yoshiro Maezawa; Kenichi Sakamoto; Daigaku Uchida; Susumu Nakamura; Masaya Yamaga; Hidetaka Yokoh; Akina Kobayashi; Shunichiro Onishi; Kazuki Kobayashi; Jun Ogino; Naotake Hashimoto; Hirotake Tokuyama; Fumio Shimada; Emi Ohara; Takahiro Ishikawa; Mayumi Shoji; Shintaro Ide; Kana Ide; Yusuke Baba; Akiko Hattori; Takumi Kitamoto; Takuro Horikoshi; Ryota Shimofusa; Sho Takahashi; Kengo Nagashima; Yasunori Sato; Minoru Takemoto; Laura Kristin Newby; Koutaro Yokote;

doi:10.1111/dom.13750

Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

Diabetes Obesity and Metabolism ◽

10.1111/dom.13750 ◽

2019 ◽

Vol 21 (8) ◽

pp. 1990-1995 ◽

Cited By ~ 5

Author(s):

Masaya Koshizaka ◽

Ko Ishikawa ◽

Ryoichi Ishibashi ◽

Yoshiro Maezawa ◽

Kenichi Sakamoto ◽

...

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Randomized Controlled Study ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Randomized Controlled ◽

Fat Reduction

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review5 ◽

2019 ◽

Author(s):

Christine Mermier

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review2 ◽

2019 ◽

Author(s):

Christine Mermier

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review2 ◽

2019 ◽

Author(s):

Zhengxiang Huang

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Decision letter for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review4 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Decision letter for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review3 ◽

2019 ◽

Author(s):

Simone Perna

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text

Author response for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v3/response1 ◽

2019 ◽

Author(s):

Masaya Koshizaka ◽

Ko Ishikawa ◽

Ryoichi Ishibashi ◽

Yoshiro Maezawa ◽

Kenichi Sakamoto ◽

...

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text